m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05153
|
[1], [2] | |||
Non-coding RNA
miR-103-3p
METTL14
lncRNA miRNA circRNA
Direct
Inhibition
m6A modification
P4HB
P4HB
METTL14
Methylation
 : m6A sites
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Methyltransferase-like 14 (METTL14) | WRITER | |||
| m6A Target | Protein disulfide-isomerase (P4HB) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | hsa-miR-103-3p | microRNA | View Details | ||
| Regulated Target | Methyltransferase-like protein 14 (METTL14) | View Details | |||
| Crosstalk Relationship | ncRNA → m6A | Inhibition | |||
| Crosstalk Mechanism | ncRNAs directly impacts m6A modification through modulating the expression level of m6A regulator | ||||
| Crosstalk Summary | hsa-miR-103-3p targets the m6 A methyltransferase METTL14 to inhibit osteoblastic bone formation.METTL14 knockdown overturned the promotive effects of ICA on Protein disulfide-isomerase (P4HB) m6A level and BMSC osteogenic differentiation. To sum up, ICA elevated the METTL14-mediated m6A modification of P4HB to facilitate BMSC osteogenic differentiation. | ||||
| Responsed Disease | Osteoporosis | ICD-11: FB83.1 | |||
| Responsed Drug | ICARIIN | ||||
| In-vivo Model | After anesthesia with ketamine-xylazine(intraperitoneal injection, 60 and 5 mg/kg, respectively), the rats were operated to remove the bilateral ovaries. For the rats in the Sham group, only the fat around the ovaries was surgically removed. Four weeks after the operation, the animals were orally treated with ICA (250 mg/kg) daily for 10 weeks . | ||||
References